Suntinorexton Explained

Width:	225px
Routes Of Administration:	By mouth
Cas Number:	2274802-89-8
Unii:	FF2NQ35DA4
Pubchem:	137460941
Iupac Name:	N-[(2''S'',3''S'')-2-[[2-fluoro-3-(3-fluorophenyl)phenyl]methyl]-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl]ethanesulfonamide
C:	23
H:	28
F:	2
N:	2
O:	4
S:	1
Smiles:	CCS(=O)(=O)N[C@H]1CCN([C@H]1CC2=C(C(=CC=C2)C3=CC(=CC=C3)F)F)C(=O)C(C)(C)O
Stdinchi:	1S/C23H28F2N2O4S/c1-4-32(30,31)26-19-11-12-27(22(28)23(2,3)29)20(19)14-16-8-6-10-18(21(16)25)15-7-5-9-17(24)13-15/h5-10,13,19-20,26,29H,4,11-12,14H2,1-3H3/t19-,20-/m0/s1
Stdinchikey:	MQDUVMBBJZLFHF-PMACEKPBSA-N

Suntinorexton (; developmental code name TAK-861) is an experimental orexin receptor agonist.^{[1] [2]} It acts as a selective agonist of the orexin OX₂ receptor and was described in 2019 in a patent by Takeda Pharmaceutical Company.^[3] Suntinorexton has superseded danavorexton (TAK-925) and firazorexton (TAK-994) as a clinical drug candidate owing to toxicity of these agents. The drug has reached phase 3 clinical trials as of 2024.^[4] It is orally active and centrally penetrant.

See also

• Orexin receptor § Agonists
• List of investigational sleep drugs § Orexin receptor agonists

Notes and References

1. Konofal . Eric . From past to future: 50 years of pharmacological interventions to treat narcolepsy . Pharmacology Biochemistry and Behavior . 241 . 2024 . 10.1016/j.pbb.2024.173804 . 173804. free .
2. International Nonproprietary Names for Pharmaceutical Substances (INN) . WHO Drug Information . 34 . 1 . 2020 . 93–269 . Proposed INN: List 123 .
3. WO . 2019027058 . application . Heterocyclic compound and use therof . Kajita Y, Mikami S, Miyanohana Y, Koike T, Daini M, Oyabu N, Ogino M, Takeuchi K, Ito Y, Tokunaga N, Sugimoto T, Miyazaki T, Oda T, Hoashi Y, Hattori Y, Imamura K . . 2019-02-07 . . .
4. Web site: TAK 861 . AdisInsight . 12 July 2024 . 30 July 2024.